101
|
Najahi-Missaoui W, Arnold RD, Cummings BS. Safe Nanoparticles: Are We There Yet? Int J Mol Sci 2020; 22:ijms22010385. [PMID: 33396561 PMCID: PMC7794803 DOI: 10.3390/ijms22010385] [Citation(s) in RCA: 175] [Impact Index Per Article: 43.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 12/24/2020] [Accepted: 12/27/2020] [Indexed: 12/14/2022] Open
Abstract
The field of nanotechnology has grown over the last two decades and made the transition from the benchtop to applied technologies. Nanoscale-sized particles, or nanoparticles, have emerged as promising tools with broad applications in drug delivery, diagnostics, cosmetics and several other biological and non-biological areas. These advances lead to questions about nanoparticle safety. Despite considerable efforts to understand the toxicity and safety of these nanoparticles, many of these questions are not yet fully answered. Nevertheless, these efforts have identified several approaches to minimize and prevent nanoparticle toxicity to promote safer nanotechnology. This review summarizes our current knowledge on nanoparticles, their toxic effects, their interactions with mammalian cells and finally current approaches to minimizing their toxicity.
Collapse
Affiliation(s)
- Wided Najahi-Missaoui
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA;
- Correspondence: ; Tel.: +1-706-542-6552; Fax: +70-6542-5358
| | - Robert D. Arnold
- Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA;
- Interdisciplinary Toxicology Program, University of Georgia, Athens, GA 30602, USA
| | - Brian S. Cummings
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA;
- Interdisciplinary Toxicology Program, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
102
|
Alshehri S, Imam SS, Rizwanullah M, Akhter S, Mahdi W, Kazi M, Ahmad J. Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges. Pharmaceutics 2020; 13:E24. [PMID: 33374391 PMCID: PMC7823416 DOI: 10.3390/pharmaceutics13010024] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 12/18/2020] [Accepted: 12/22/2020] [Indexed: 12/12/2022] Open
Abstract
Early detection, right therapeutic intervention, and simultaneous effectiveness mapping are considered the critical factors in successful cancer therapy. Nevertheless, these factors experience the limitations of conventional cancer diagnostics and therapeutics delivery approaches. Along with providing the targeted therapeutics delivery, advances in nanomedicines have allowed the combination of therapy and diagnostics in a single system (called cancer theranostics). This paper discusses the progress in the pre-clinical and clinical development of therapeutics, diagnostics, and theranostics cancer nanomedicines. It has been well evident that compared to the overabundance of works that claimed success in pre-clinical studies, merely 15 and around 75 cancer nanomedicines are approved, and currently under clinical trials, respectively. Thus, we also brief the critical bottlenecks in the successful clinical translation of cancer nanomedicines.
Collapse
Affiliation(s)
- Sultan Alshehri
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; (S.A.); (S.S.I.); (W.M.); (M.K.)
- Department of Pharmaceutical Sciences, College of Pharmacy, Almaarefa University, Riyadh 11597, Saudi Arabia
| | - Syed Sarim Imam
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; (S.A.); (S.S.I.); (W.M.); (M.K.)
| | - Md. Rizwanullah
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; or
| | - Sohail Akhter
- New Product Development, Global R&D, Sterile ops, TEVA Pharmaceutical Industries Ltd., Aston Ln N, Halton, Preston Brook, Runcorn WA7 3FA, UK;
| | - Wael Mahdi
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; (S.A.); (S.S.I.); (W.M.); (M.K.)
| | - Mohsin Kazi
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; (S.A.); (S.S.I.); (W.M.); (M.K.)
| | - Javed Ahmad
- Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia
| |
Collapse
|
103
|
Nie X, Chen Z, Pang L, Wang L, Jiang H, Chen Y, Zhang Z, Fu C, Ren B, Zhang J. Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds. Int J Nanomedicine 2020; 15:10215-10240. [PMID: 33364755 PMCID: PMC7751584 DOI: 10.2147/ijn.s285134] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2020] [Accepted: 11/23/2020] [Indexed: 12/15/2022] Open
Abstract
In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.
Collapse
Affiliation(s)
- Xin Nie
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Zhejie Chen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of China
| | - Lan Pang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Lin Wang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Huajuan Jiang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Yi Chen
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Zhen Zhang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Chaomei Fu
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Bo Ren
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| | - Jinming Zhang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu611137, People’s Republic of China
| |
Collapse
|
104
|
Arévalo-Pérez R, Maderuelo C, Lanao JM. Recent advances in colon drug delivery systems. J Control Release 2020; 327:703-724. [DOI: 10.1016/j.jconrel.2020.09.026] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 09/11/2020] [Accepted: 09/12/2020] [Indexed: 12/12/2022]
|
105
|
Chen Z, Xu L, Gao X, Wang C, Li R, Xu J, Zhang M, Panichayupakaranant P, Chen H. A multifunctional CeO 2@SiO 2-PEG nanoparticle carrier for delivery of food derived proanthocyanidin and curcumin as effective antioxidant, neuroprotective and anticancer agent. Food Res Int 2020; 137:109674. [PMID: 33233251 DOI: 10.1016/j.foodres.2020.109674] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 08/04/2020] [Accepted: 09/06/2020] [Indexed: 02/05/2023]
Abstract
The nanoparticle systems could effectively overcome the drug delivery challenges of food bioactive compounds. In this study, a novel and effective multifunctional PEG modified CeO2@SiO2 nanoparticle (CSP-NPs) system was successfully fabricated. Food derived proanthocyanidin (PAC) and curcumin (Cur) were loaded onto CSP-NPs and formed as PAC-NPs and Cur-NPs. Fourier transform Infrared spectra, X-ray diffraction, scanning electron microscopy, transmission electron microscopy, and dynamic light scattering were used to characterize the prepared NPs. CSP-NPs, PAC-NPs and Cur-NPs displayed spherical shape with about 35-45 nm size. The bioactivity analysis revealed that CSP-NPs system could effectively deliver PAC and Cur to exhibit strong antioxidant activity, potent neuroprotective effect against Aβ1-42-mediated toxicity in PC-12 cells (recovered cell viability from 57.5% to 81.0% at the dose of 25 μg/mL) and effective antiproliferative effects on HepG2 and Hela cells. Besides, all prepared nanoparticles (0-100 µg/ml) used in this study showed no significant toxicity on cell models of antioxidative and neuroprotective activities, excepting for cancer cells, suggesting that these nanoparticles had the potential of being utilized in drug delivery. Therefore, CSP-NPs might be a promising delivery system for hydrophilic molecule proanthocyanidin and hydrophobic molecule curcumin against the oxidative damage, neurodegenerative diseases and cancer, which could facilitate the application of food derived nutrients in functional foods industry.
Collapse
Affiliation(s)
- Zhongqin Chen
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China
| | - Leilei Xu
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China
| | - Xudong Gao
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China
| | - Chunli Wang
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China
| | - Ruilin Li
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China
| | - Jun Xu
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China
| | - Min Zhang
- Tianjin Agricultural University, Tianjin 300384, PR China; State Key Laboratory of Nutrition and Safety, Tianjin University of Science & Technology, Tianjin 300457, PR China
| | - Pharkphoom Panichayupakaranant
- Phytomedicine and Pharmaceutical Biotechnology Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla 90112, Thailand
| | - Haixia Chen
- Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China.
| |
Collapse
|
106
|
Elgamouz A, Idriss H, Nassab C, Bihi A, Bajou K, Hasan K, Abu Haija M, Patole SP. Green Synthesis, Characterization, Antimicrobial, Anti-Cancer, and Optimization of Colorimetric Sensing of Hydrogen Peroxide of Algae Extract Capped Silver Nanoparticles. NANOMATERIALS (BASEL, SWITZERLAND) 2020; 10:E1861. [PMID: 32957557 PMCID: PMC7557820 DOI: 10.3390/nano10091861] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 09/08/2020] [Accepted: 09/11/2020] [Indexed: 12/21/2022]
Abstract
A green and cost-effective technique for the preparation of silver nanoparticles (Algae-AgNPs) as a colorimetric sensor for hydrogen peroxide (H2O2) is described. Silver nanoparticles were capped using the green algae (Noctiluca scintillans) extract at an optimum time of 3 h at 80 °C. The pH of the plant extract (pH = 7.0) yields nanoparticles with a mean size of 4.13 nm and a zeta potential of 0.200 ± 0.02 mV and negative polarity, using dynamic light scattering (DLS). High-resolution transmission electron microscopy (HRTEM) analysis showed regular spherical particles with the average size of 4.5 nm. Selected area electron diffraction (SAED) results revealed the polycrystalline nature of the silver nanoparticles. The obtained patterns were indexed as (111), (200), (220), and (311) reflections of the fcc (face centered cubic) silver crystal based on their d-spacing of 2.47, 2.13, 1.49, and 1.27 Å, respectively. The apparent color change from brown to colorless was observed when nanoparticles reacted with H2O2. Linear responses were obtained in three different ranges (nM, µM, and mM). Limits of detection (LOD) of 1.33 ± 0.02 and 1.77 ± 0.02 nM and quantitation limits (LOQ) of 7.31 ± 0.03 and 9.67 ± 0.03 nM were obtained for Abs and ΔAbs calibration curves, respectively. 10% v/v Algae-AgNPs solution inhibited Staphylococcus aureus over Escherichia coli, while a 50% reduction of tumor cell growth of MDA-MB-231 human breast adenocarcinoma was obtained.
Collapse
Affiliation(s)
- Abdelaziz Elgamouz
- Department of Chemistry, College of Sciences, University of Sharjah, Sharjah PO. Box 27272, UAE; (H.I.); (C.N.); (A.B.); (K.H.)
| | - Hamid Idriss
- Department of Chemistry, College of Sciences, University of Sharjah, Sharjah PO. Box 27272, UAE; (H.I.); (C.N.); (A.B.); (K.H.)
| | - Chahlaa Nassab
- Department of Chemistry, College of Sciences, University of Sharjah, Sharjah PO. Box 27272, UAE; (H.I.); (C.N.); (A.B.); (K.H.)
| | - Alaa Bihi
- Department of Chemistry, College of Sciences, University of Sharjah, Sharjah PO. Box 27272, UAE; (H.I.); (C.N.); (A.B.); (K.H.)
| | - Khalid Bajou
- Department of Applied Biology, College of Sciences, University of Sharjah, Sharjah PO. Box 27272, UAE;
| | - Kamrul Hasan
- Department of Chemistry, College of Sciences, University of Sharjah, Sharjah PO. Box 27272, UAE; (H.I.); (C.N.); (A.B.); (K.H.)
| | - Mohammad Abu Haija
- Department of Chemistry, Khalifa University of Science and Technology, Abu Dhabi PO. Box 127788, UAE;
| | - Shashikant P. Patole
- Department of Physics, Khalifa University of Science and Technology, Abu Dhabi PO. Box 127788, UAE;
| |
Collapse
|
107
|
|
108
|
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics 2020; 12:pharmaceutics12090837. [PMID: 32882875 PMCID: PMC7559885 DOI: 10.3390/pharmaceutics12090837] [Citation(s) in RCA: 83] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/25/2020] [Accepted: 08/28/2020] [Indexed: 12/13/2022] Open
Abstract
Nanotechnologies have attracted increasing attention in their application in medicine, especially in the development of new drug delivery systems. With the help of nano-sized carriers, drugs can reach specific diseased areas, prolonging therapeutic efficacy while decreasing undesired side-effects. In addition, recent nanotechnological advances, such as surface stabilization and stimuli-responsive functionalization have also significantly improved the targeting capacity and therapeutic efficacy of the nanocarrier assisted drug delivery system. In this review, we evaluate recent advances in the development of different nanocarriers and their applications in therapeutics delivery.
Collapse
|
109
|
Crist RM, Dasa SSK, Liu CH, Clogston JD, Dobrovolskaia MA, Stern ST. Challenges in the development of nanoparticle-based imaging agents: Characterization and biology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2020; 13:e1665. [PMID: 32830448 DOI: 10.1002/wnan.1665] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 07/13/2020] [Accepted: 07/14/2020] [Indexed: 12/15/2022]
Abstract
Despite imaging agents being some of the earliest nanomedicines in clinical use, the vast majority of current research and translational activities in the nanomedicine field involves therapeutics, while imaging agents are severely underrepresented. The reasons for this lack of representation are several fold, including difficulties in synthesis and scale-up, biocompatibility issues, lack of suitable tissue/disease selective targeting ligands and receptors, and a high bar for regulatory approval. The recent focus on immunotherapies and personalized medicine, and development of nanoparticle constructs with better tissue distribution and selectivity, provide new opportunities for nanomedicine imaging agent development. This manuscript will provide an overview of trends in imaging nanomedicine characterization and biocompatibility, and new horizons for future development. This article is categorized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.
Collapse
Affiliation(s)
- Rachael M Crist
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA
| | - Siva Sai Krishna Dasa
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA
| | - Christina H Liu
- Nanodelivery Systems and Devices Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland, USA
| | - Jeffrey D Clogston
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA
| | - Marina A Dobrovolskaia
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA
| | - Stephan T Stern
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA
| |
Collapse
|
110
|
Mohammadpour R, Cheney DL, Grunberger JW, Yazdimamaghani M, Jedrzkiewicz J, Isaacson KJ, Dobrovolskaia MA, Ghandehari H. One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility. J Control Release 2020; 324:471-481. [PMID: 32464151 PMCID: PMC7429347 DOI: 10.1016/j.jconrel.2020.05.027] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 05/14/2020] [Accepted: 05/16/2020] [Indexed: 02/06/2023]
Abstract
Chronic toxicity evaluations of nanotechnology-based drugs are essential to support initiation of clinical trials. Ideally such evaluations should address the dosing strategy in human applications and provide sufficient information for long-term usage. Herein, we investigated one-year toxicity of non-surface modified silica nanoparticles (SNPs) with variations in size and porosity (Stöber SNPs 46 ± 4.9 and 432.0 ± 18.7 nm and mesoporous SNPs 466.0 ± 86.0 nm) upon single dose intravenous administration to female and male BALB/c mice (10 animal/sex/group) along with their human blood compatibility. Our evidence of clinical observation and blood parameters showed no significant changes in body weight, cell blood count, nor plasma biomarker indices. No significant changes were noted in post necropsy examination of internal organs and organ-to-body weight ratio. However, microscopic examination revealed significant amount of liver inflammation and aggregates of histocytes with neutrophils within the spleen suggesting an ongoing or resolving injury. The fast accumulation of these plain SNPs in the liver and spleen upon IV administration and the duration needed for their clearance caused these injuries. There were also subtle changes which were attributed to prior infarctions or resolved intravascular thrombosis and included calcifications in pulmonary vessels, focal cardiac fibrosis with calcifications, and focal renal injury. Most of the pathologic lesions were observed when large, non-porous SNPs were administered. Statistically significant chronic toxicity was not observed for the small non-porous particles and for the mesoporous particles. This one-year post-exposure evaluation indicate that female and male BALB/c mice need up to one year to recover from acute tissue toxic effects of silica nanoparticles upon single dose intravenous administration at their 10-day maximum tolerated dose. Further, ex vivo testing with human blood and plasma revealed no hemolysis or complement activation following incubation with these silica nanoparticles. These results can inform the potential utility of silica nanoparticles in biomedical applications such as controlled drug delivery where intravenous injection of the particles is intended.
Collapse
Affiliation(s)
- Raziye Mohammadpour
- Utah Center for Nanomedicine, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States
| | - Darwin L Cheney
- Utah Center for Nanomedicine, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States
| | - Jason W Grunberger
- Utah Center for Nanomedicine, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States
| | - Mostafa Yazdimamaghani
- Utah Center for Nanomedicine, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States
| | - Jolanta Jedrzkiewicz
- Department of Pathology, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States
| | - Kyle J Isaacson
- Utah Center for Nanomedicine, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, United States
| | - Marina A Dobrovolskaia
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, United States
| | - Hamidreza Ghandehari
- Utah Center for Nanomedicine, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, Nano Institute of Utah, and University of Utah, Salt Lake City, Utah, United States; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, United States.
| |
Collapse
|
111
|
Asha Spandana K, Bhaskaran M, Karri V, Natarajan J. A comprehensive review of nano drug delivery system in the treatment of CNS disorders. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101628] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
112
|
Guo J, Huang L. Membrane-core nanoparticles for cancer nanomedicine. Adv Drug Deliv Rev 2020; 156:23-39. [PMID: 32450105 DOI: 10.1016/j.addr.2020.05.005] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 05/16/2020] [Accepted: 05/18/2020] [Indexed: 12/13/2022]
Abstract
Cancer is one of the most severe disease burdens in modern times, with an estimated increase in the number of patients diagnosed globally from 18.1 million in 2018 to 23.6 million in 2030. Despite a significant progress achieved by conventional therapies, they have limitations and are still far from ideal. Therefore, safe, effective and widely-applicable treatments are urgently needed. Over the past decades, the development of novel delivery approaches based on membrane-core (MC) nanostructures for transporting chemotherapeutics, nucleic acids and immunomodulators has significantly improved anticancer efficacy and reduced side effects. In this review, the formulation strategies based on MC nanostructures for delivery of anticancer drug are described, and recent advances in the application of MC nanoformulations to overcome the delivery hurdles for clinical translation are discussed.
Collapse
|
113
|
Maestri CA, Motta A, Moschini L, Bernkop-Schnürch A, Baus RA, Lecca P, Scarpa M. Composite nanocellulose-based hydrogels with spatially oriented degradation and retarded release of macromolecules. J Biomed Mater Res A 2020; 108:1509-1519. [PMID: 32175650 DOI: 10.1002/jbm.a.36922] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 02/27/2020] [Accepted: 03/09/2020] [Indexed: 12/24/2022]
Abstract
The oral delivery of macromolecular therapeutics to the intestinal tract requires novel, robust, and controlled formulations. Here, we report on fabrication by molding of composite hydrogel cylinders made of cellulose nanocrystals (CNCs) and chitosan (Cht) and their performance as delivery vehicles. CNCs provide excellent mechanical and chemical stress resistance, whereas Cht allows scaffold degradation by enzyme digestion. The release of a representative medium size protein (bovine serum albumin) dispersed in the hydrogel is slow and shows a sigmoidal profile; meanwhile, the hydrogel scaffold degrades according to a preferred route, that is the cylinder is eroded along the vertical axis. The cup-like, scarcely interconnected porous network, with a gradient of hardness along the cylinder axis, and the compact skin-like layer covering the lateral wall which stayed in contact with the mold during gelification, explain the preferred erosion direction and the long-term protein release. The possible effect of the molding process on hydrogel structure suggests that molding could be a simple and cheap way to favor surface compaction and directional scaffold degradation.
Collapse
Affiliation(s)
| | - Antonella Motta
- Department of Industrial Engineering and Biotech Centre, University of Trento, Trento, Italy
| | - Lorenzo Moschini
- Department of Industrial Engineering and Biotech Centre, University of Trento, Trento, Italy
| | | | | | - Paola Lecca
- Department of Mathematics, University of Trento, Povo-Trento, Italy
| | - Marina Scarpa
- Department of Physics, University of Trento, Povo-Trento, Italy
| |
Collapse
|
114
|
Joseph SK, Sabitha M, Nair SC. Stimuli-Responsive Polymeric Nanosystem for Colon Specific Drug Delivery. Adv Pharm Bull 2020; 10:1-12. [PMID: 32002356 PMCID: PMC6983990 DOI: 10.15171/apb.2020.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 09/25/2019] [Accepted: 09/30/2019] [Indexed: 12/16/2022] Open
Abstract
An ideal colon specific drug delivery system needs to perform multiple functions like greater bio availability, less toxicity and higher therapeutic efficacy, all of which require high degree of smartness. This article focuses on the overview of the stimuli-responsive polymers and various nanodrug delivery systems which have found applications in colon specific delivery of drugs as this system provide a link between therapeutic need and drug delivery. These polymers exhibit a non-linear response to a small stimulus leading to a macroscopic alteration in their structure/properties. Stimuli responsive polymers display a significant physio chemical change in response to small changes in their environment (temperature, pH, light etc.). Colonic drug delivery has gained increased importance in treating diseases like Crohn's disease, ulcerative colitis, colon cancer etc. The expansion in the development of polymers based system with greater flexibility, versatility and unexplored potential enables new opportunities for them in uplifting bio medicine. Applying the concepts of smartness in the context of clinically relevant therapeutic and diagnostic systems, it can prelude in a new era of 'smart' therapeutics that can improve the health care fields. In particular, due to its high sensitivity to the stimuli, this system has been identified as a sensible platform for releasing drug at suitable site and at appropriate time.
Collapse
Affiliation(s)
- Sharon Kunnath Joseph
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India
| | - Mangalath Sabitha
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India
| | | |
Collapse
|
115
|
Qamar Z, Qizilbash FF, Iqubal MK, Ali A, Narang JK, Ali J, Baboota S. Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective. RECENT PATENTS ON DRUG DELIVERY & FORMULATION 2019; 13:246-254. [PMID: 31884933 PMCID: PMC7499345 DOI: 10.2174/1872211314666191224115211] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 10/21/2019] [Accepted: 10/29/2019] [Indexed: 01/09/2023]
Abstract
The structure of the eye is very complex in nature which makes it a challenging task for pharmaceutical researchers to deliver the drug at the desired sites via different routes of administration. The development of the nano-based system helped in delivering the drug in the desired concentration. Improvement in penetration property, bioavailability, and residence time has all been achieved by encapsulating drugs into liposomes, dendrimers, solid lipid nanoparticle, nanostructured lipid carrier, nanoemulsion, and nanosuspension. This review puts emphasis on the need for nanomedicine for ocular drug delivery and recent developments in the field of nanomedicine along with recent patents published in the past few years.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sanjula Baboota
- Address correspondence to this author at the Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi -110062, India; Tel: +919818529286; E-mail:
| |
Collapse
|